A dose-ranging pharmacokinetic study of nicotine tartrate following single-dose delayed-release oral and intravenous administration

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 5, 1997, Pages 865-874

  Compton, R F ^a,f   Sandborn, W J ^b   Lawson, G M ^c   Sheets, A J ^d   Mays, D C ^e   Zins, B J ^f   Tremaine, W J ^g   Lipsky, J J ^h   Mahoney, D W ^g   Zinsmeister, A R ^b   Offord, K P ^c   Hurth, R D ^d   Evans, B K ^e   Green, J ^f  

^a Division of Gastroenterology   (United Kingdom)

^b Department of Laboratory Medicine and Pathology ^*  (United Kingdom)

^c Division of Clinical Pharmacology   (United Kingdom)

^d Section of Biostatistics   (United Kingdom)

^e Nicotine Research Center   (United Kingdom)

^f MAYO CLINIC   (United States)

^g LLANDOUGH HOSPITAL   (United Kingdom)

^h UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COTININE; DRUG METABOLITE; EUDRAGIT; NICOTINE TARTRATE;

AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DIAPHORESIS; DRUG BLOOD LEVEL; DRUG DETERMINATION; GAS CHROMATOGRAPHY; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; INTRAGASTRIC DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MASS SPECTROMETRY; MICROCAPSULE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; QUESTIONNAIRE; SUSTAINED RELEASE FORMULATION; TREMOR; ULCERATIVE COLITIS; VERTIGO; VOMITING;

EID: 9844247982     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.00236.x     Document Type: Article

References (25)

1. Harries AD, Baird A, Rhodes ]. Non-smoking: a feature of ulcerative colitis. Br Med ] 1982; 284: 706.
2. Jick H, Walker AM. Cigarette smoking and ulcerative colitis. N Engl }Med 1983; 308: 261-3.
3. Boyko EJ, Koepsell TD, Perera DR, Inui TS. Risk of ulcerative colitis among former and current cigarette smokers. N Engl J Med 1987; 316: 707-10.
4. Motley RJ, Rhodes J, Ford GA, et al. Time relationships between cessation of smoking and onset of ulcerative colitis. Digestion 1987; 37: 125-7.
5. Rudra T, Motley R, Rhodes J. Does smoking improve colitis. Scand J Gastroenterol 1989; 24(Suppl. 170): 61-3.
6. Roberts CJ, Diggle R. Non-smoking: a feature of ulcerative colitis. Br Med J 1982; 285: 440.
7. Lashner BA, Hanauer SB, Silverstein MD. Testing nicotine gum for ulcerative colitis patients. Experience with single-patient trials. Dig Dis Sei 1990; 35: 827-32.
8. Srivastava ED. Russell MAH, Feyerabend C, et al. Transdermal nicotine in active ulcerative colitis. Eur J Gastroenterol Hepatol 1991; 3: 815-8.
9. Pullan RD, Rhodes J, Ganesh S, et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994; 330: 811-5.
10. Sandborn WJ, Tremaine WJ. OfTord KP, ft al Transdermal nicotine for mildly to moderately active ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126: 364-71.
11. Thomas GAO, Rhodes J, Ragunath K, et al Transdermal nicotine compared with oral prednisolone therapy for active ulcerative colitis. Eur J Gastroenterol Hepatol 1996; 8: 769-76.
12. Thomas GAO, Rhodes J, Mani V, et al. Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med 1995; 332: 988-92.
13. Zins BJ, Sandborn WJ, Mays DC, et al. Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous nicotine tartrate administration. J Clin Pharmacol 1997; 37: 426-36.
14. Green JT, Thomas GAO, Rhodes J, et al. Pharmacokinetics of nicotine carbomer enemas: a new treatment for ulcerative colitis. Clin Pharmacol Ther 1997; 61: 340-8.
15. Sandborn WJ, Tremaine WJ, Leighton JA, et al. Nicotine tartrate liquid enemas for mildly to moderately active, leftsided ulcerative colitis unresponsive to first-line therapy: a pilot study. Aliment Pharmacol Ther 1997; 11: 663-671.
16. Green JT, Thomas GAO, Rhodes J, et al. Nicotine enemas for ulcerative colitis-a pilot study. Aliment Pharmacol Ther 1997; 11: 859-863.
17. Baskin L. Charlson J, Chezick P, Lawson GM. Determination of serum nicotine concentration using solid phase extraction, and GC-MS with selected ion monitoring. Am J Clin Pathol 1991; 95: 272-3 (Abstract).
18. Machacek DA. Jiang N. Qualification of cotinine in plasma and saliva by liquid chromatography. Clin Chem 1986; 32: 97982.
19. Schroeder KW, Tremaine VVJ, Ilstrup DM. Coated oral 5aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 1987; 317: 1625-9.
20. Gibaldi M, Perrier D (eds.). Pharmacokinetics, 2nd edn. New York: Marcel Dekker, 1982: 409-17.
21. Bannon YB, Corish J, Corrigan OI, et al Transdermal delivery of nicotine in normal human volunteers: a single dose and multiple dose study. Eur J Clin Pharmacol 1989; 37: 28590.
22. Mulligan SC, Masterson JG, Devane JG, Kelly JG. Clinical and pharmacokinetic properties of a transdermal nicotine patch. Clin Pharmacol Ther 1990; 47: 331-7.
23. Benowitz NL, Jacob P, Denaro C, Jenkins R. Stable isotope studies of nicotine kinetics and bioavailability. Clin Pharmacol Ther 1991; 49: 270-7.
24. Cohen RD, Hanauer SB. Nicotine in ulcerative colitis. How does it work and how can we use it? Clin Immunother 1996; 5: 169-74.
25. Bhatti MA, Hodgson HJF. Nicotine down-regulates IL-8 production and tissue expression in inflammatory bowel disease. Gastroenterology 1997: 112: A934 (Abstract).